 WATERTOWN, Mass., Nov. 01, 2021 GLOBE NEWSWIRE -- Kymera Therapeutics, Inc. NASDAQ: KYMR, a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will participate in several upcoming virtual investor conferences: 